Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805550 | 0.81 | SLC22A12 (0.43) | MAOB | |
| SCHEMBL7266539 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2MAOBITGA4ITGB1KMT2A | |
| SCHEMBL7266467 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2MAOBITGA4ITGB1KMT2A | |
| SCHEMBL13110148 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2MAOBITGA4ITGB1KMT2A | |
| SCHEMBL3334242 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2ITGA4ITGB1KMT2AMEN1 | |
| SCHEMBL3334244 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2ITGA4ITGB1KMT2AMEN1 | |
| SCHEMBL6602394 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2MAOBITGA4ITGB1KMT2A | |
| SCHEMBL3499309 | 0.76 | NR1H4 (0.58) | SMN1; SMN2ITGA4ITGB1NR1H4 | |
| SCHEMBL6805048 | 0.76 | LMNA (0.58) | SMN1; SMN2MAOBRAB9A | |
| SCHEMBL6804479 | 0.75 | MAOB (0.47) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770647-B2 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |